Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** \n3'-deoxy‐3'-aminothymidine monophosphate is a synthetic nucleotide analog and phosphorylated derivative of thymidine. It features an amino group at the 3' position in place of the usual hydroxyl group and is phosphorylated at the 5' position. This compound belongs to the class of pyrimidones and has been studied as an experimental molecule with potential applications in antiviral therapy due to its structural similarity to natural nucleotides. Its mechanism likely involves incorporation into DNA or RNA chains by viral polymerases or interference with nucleic acid synthesis; however, it is not approved for clinical use and remains primarily a research tool[1][2]. \nThe compound has also been identified as a catabolite related to certain antiretroviral drugs (such as AZT), where it may contribute to cytotoxicity[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3'-deoxy-3'-aminothymidine monophosphate.